

NOVADEL PHARMA INC

Form 8-K

January 07, 2011

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): January 7, 2011

NOVADEL PHARMA INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or other jurisdiction
of incorporation or
organization)

001-32177
(Commission File No.)

22-2407152
(I.R.S. Employer
Identification No.)

1200 Route 22 East, Suite 2000
Bridgewater, NJ 08807
(Address of principal executive offices) (Zip Code)

(908) 203-4640
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
-

Edgar Filing: NOVADEL PHARMA INC - Form 8-K

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On January 7, 2011, NovaDel Pharma Inc., a Delaware corporation (the “Company”), issued a press release to announce that the Company received a milestone payment of \$500,000 from Akrimax Pharmaceuticals, Inc. (“Akrimax”) in connection with the License and Distribution Agreement, dated October 27, 2009 (the “Agreement”) between the Company and Mist Acquisition, LLC (“Mist”), a subsidiary of Akrimax. As previously disclosed, the Agreement provides Akrimax with a license to commercialize and manufacture NitroMist® in North America, using the Company’s spray delivery technology.

Akrimax also advised the Company that it has successfully launched NitroMist in the United States.

Item 9.01 Financial Statements and Exhibits.

(d)	Exhibits
Exhibit No.	Description
99.1	Press Release of NovaDel Pharma Inc. dated January 7, 2011, titled “NovaDel Pharma Inc. Receives \$500,000 Milestone Payment-NitroMist® Launched in United States.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NovaDel Pharma
Inc.

By: /s/
STEVEN
B.
RATOFF
Name: Steven B.
Ratoff
Title: President
and Chief
Executive
Officer

Date: January 7, 2011
